Maria Rapicetta

Maria Rapicetta

Auto-generated profile, based on publicly available information

Maria Rapicetta

Istituto Superiore di Sanita

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2006 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
LKLoreta A Kondili
Loreta A Kondili
DGD. Genovese
D. Genovese
CAC. Argentini
C. Argentini
PCP. Chionne
P. Chionne
PTP. Toscani
P. Toscani
MRM. Rapicetta
M. Rapicetta

1 April 2005 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
DGD. Genovese
D. Genovese
SDS. Dettori
S. Dettori
CAC. Argentini
C. Argentini
UVU. Villano
U. Villano
PCP. Chionne
P. Chionne
MRM. Rapicetta
M. Rapicetta
We analyzed hepatitis C virus (HCV) genotype 4 isolates circulating in the Alexandria District (Egypt) in terms of genetic divergence and the presence of different subtypes. Hypervariable region 1 (HVR1) and the NH2 region of the E2 protein were characterized, and the heterogeneity of subtype 4a isolates was evaluated by analyzing epitope frequencies, immunoproteasome prediction, and possible glycosylation patterns. The heterogeneity of the nucleotide sequences was greater than that found in previous studies, which reported only subtype 4a. Subtype 4a was most common (78% of cases), yet four new subtypes were found, with subtype 4m representing 11% of the cases and the other three subtypes representing another 11%. Substantial heterogeneity was also found when the intrasubtype 4a sequences were analyzed. Differences in the probability of glycosylation and in the positions of the different sites were also observed. The analysis of the predicted cytotoxic-T-lymphocyte epitopes showed differences in both the potential proteosome cleavage and the prediction score. The Egyptian isolates in our study also showed high variability in terms of the HVR1 neutralization epitope. Five of these isolates showed amino acid substitutions never previously observed (a total of six positions). Four of these residues (in four different isolates) were in positions involved in anchoring to the E2 glycoprotein core and in maintaining the HVR1 conformation. The results of this study indicate that HCV genotype 4 in Egypt is extremely variable, not only in terms of sequence, but also in terms of functional and immunological determinants. These data should be taken into account in planning the development of vaccine trials in Egypt.

1 May 2002 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
GMG. Morace
G. Morace
FAF.A. Aulicino
F.A. Aulicino
CAC. Angelozzi
C. Angelozzi
LCL. Costanzo
L. Costanzo
FDF. Donadio
F. Donadio
MRM. Rapicetta
M. Rapicetta
Aims: The persistent circulation of hepatitis A virus (HAV) in the Mediterranean area suggests the need for monitoring its presence in the environment. A reverse transcriptase‐polymerase chain react...

9 April 2004 in Virus Research
Verified
Journal Article
Closed access
ACA.R Ciccaglione
A.R Ciccaglione
CMC Marcantonio
C Marcantonio
ETE Tritarelli
E Tritarelli
MEMichele Equestre
Michele Equestre
FMFabio Magurano
Fabio Magurano
MRM Rapicetta
M Rapicetta

1 April 2007 in Infection
Verified
Journal Article
Closed access
PDF file
LKLoreta A Kondili
Loreta A Kondili
DUD. Ulqinaku
D. Ulqinaku
MHM. Hajdini
M. Hajdini
MBM. Basho
M. Basho
PCP. Chionne
P. Chionne
MRM. Rapicetta
M. Rapicetta

28 July 2008 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CGCristina Giambi
Cristina Giambi
ABAntonino Bella
Antonino Bella
ABAntonella Barale
Antonella Barale
DMDomenico Montù
Domenico Montù
MMMaria Marchisio
Maria Marchisio
MAMarta L Ciofi degli Atti
Marta L Ciofi degli Atti
In 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix Hexa®), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac® was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.